Single-center experience with pegfilgrastim (P) and lenograstim (L) in nonmetastatic breast cancer (NMBC) patients (pts) during adjuvant FEC100 or sequential FEC100 plus DOCETAXEL100 (D100).

e12005 Background: Neutropenia (N) is a common chemotherapy (CT) related adverse event and febrile N (FN) often requires hospitalization, being associated with morbidity and mortality. Primary prophylaxis with G-CSF is a common strategy to avoid the onset of FN. Methods: Retrospectively, we evaluated efficacy and safety of daily injections of L (263 μg) from day 5 to 9 (5 total injections) compared with a single injection of P (6 mg) on day 2 in 55 NMBC pts (median age 55 years) during 6 cycles of FEC100 (group A) or 3 cycles of FEC100 followed by further 3 cycles of D100 (group B). Incidence of N, FN and bone pain (BP) (NRS >7) were evaluated. In group A: 35 pts (median age 54 years) received 6 cycles of FEC100. At every cycle, 17 pts received L, while 18 pts one dose of P. In group B: 20 pts (median age 55.5 years) underwent 3 cycles of FEC100 plus 3 of D100. At every cycle, 12 and 8 pts received L and P, respectively. Results: In overall population incidence of N-G3/G4 was 54.5%. In group A: G3/G4-N wa...